Previous 10 | Next 10 |
home / stock / rlftf / rlftf news
Relief Therapeutics has a found a new use for Vasoactive Intestinal Peptide by repackaging it as RLF-100 (Aviptadil) to now fight COVID. RLF-100 is still undergoing clinical Phase 2/3 trials but has already shown promising use in an emergency setup for critically ill patients. In ...
Correction of the press release published November 24, 2020: It has come to our attention that a mistake was printed in the percentage of control patients in the EAP who survived to day 28. The correct percentage is 27%, not 17% of the control patients, all treated with best available intens...
NeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients PR Newswire RADNOR, Pa. and GENEVA, Nov. 24, 2020 RADNOR, Pa....
Relief Therapeutics (RLFTF) and NeuroRx announce that more than 175 patients with Critical COVID-19 and Respiratory Failure have now been entered into an Expanded Access Protocol ((EAP)) with RLF-100 in the U.S. All patients had severe comorbidities (such as organ transplant, recent heart att...
GENEVA, SWITZERLAND / ACCESSWIRE / November 23, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today g...
Relief Therapeutics (RLFTF) appoints Syneos Health (SYNH), a global clinical research organization, to run the European clinical trial in severe COVID-19 induced lung injury, as well as future trials in other indications.Relief has also selected AMRI, a global contract development and manufac...
NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure - Observations of rapid recovery noted on chest x-ray and no drug-related Serious Adverse Events reported PR Newswire ...
Relief Therapeutics (RLFTF) with its partner NeuroRx, announce that 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase 2b/3 trial of RLF-100 (aviptadil) for treating respiratory failure in patients with critical COVID-19.So far, no drug-related serious ...
NeuroRx and Relief Therapeutics announce continuation of RLF-100™ trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020 PR Newswire RADNOR, Pa. and GENEVA, Nov. 5, 2020 RADNOR, Pa. and GENEVA , Nov. 5, ...
GENEVA, SWITZERLAND / ACCESSWIRE / November 4, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today an...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
GENEVA, SWITZARLAND / ACCESSWIRE / April 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its Annual Repo...
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call p...
GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announce...